Broker’s Call: Mankind Pharma (Buy)
Target: INR 1,520 CMP: INR 1398.15 Mankind Pharma reported its first quarterly earnings post-listing and was ahead of our estimates,
Continue readingThe Number One Finance & Business Blog!
Target: INR 1,520 CMP: INR 1398.15 Mankind Pharma reported its first quarterly earnings post-listing and was ahead of our estimates,
Continue readingTarget: INR 256 CMP: INR 210.85 Tata energyConsolidated revenue of ₹4.13% increased to Rs.1,2453.8 crore in Q4FY23 vs. Rs.11,960.0 crore
Continue readingTarget: 440 rupees CMP: INR 380.60 Bakaji’s earnings reading for the fourth quarter of fiscal 2013 sharply beat estimates, as
Continue readingTarget: 114 rupees CMP: INR 72.42 In the third quarter and the first nine months of fiscal ’23, the company
Continue readingTarget: INR 380 CMP: INR 339.65 Zensar Technologies It’s showing clear signs of a turnaround in terms of margins –
Continue readingTarget: INR 1,510 CMP: INR 1465.00 Concerns about the global box office in the post-Covid era persist as it rebounded
Continue readingTarget: INR 200 CMP: 189.35.35 Rallis India (RALI) Q4 FY23 results fell short of our expectations and consensus mainly driven
Continue reading